| Literature DB >> 35959444 |
Hongying Shan1,2, Renxin Luo1, Xuanying Guo1, Rong Li1, Zhenhong Ye1, Tianliu Peng1, Fenting Liu1, Zi Yang1.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in women of childbearing age. Individual heterogeneity is evident, and the prevalence rate ranges between 6 and 15% globally. The prevalence rate of PCOS in Chinese women of childbearing age is 5.6%. The main manifestations are infertility, sparse menstruation, irregular vaginal bleeding, long-term endometrial hyperplasia, and endometrial cancer. PCOS is often associated with hyperandrogenemia, insulin resistance, hyperinsulinemia, obesity, metabolic syndrome, and intestinal flora disorder. Although there have been many studies in the past, the underlying pathophysiological mechanism of the disease is still unclear. Studies have shown that PCOS diseases and related complications are closely related to local oxidative stress imbalance in the endometrium, leading to poor endometrial receptivity and effects on pregnancy. Previous reviews have mainly focused on the abnormal mechanism of ovarian oxidative stress in women with PCOS, while reviews on endometrial receptivity and oxidative stress are relatively insufficient. This study reviews the abnormal cellular and molecular mechanisms of oxidative stress due to comorbidities in women with PCOS, leading to a downregulation of endometrial receptivity.Entities:
Keywords: endometrial receptivity; hyperandrogenemia; molecular mechanism; oxidative stress; polycystic ovary syndrome
Year: 2022 PMID: 35959444 PMCID: PMC9357999 DOI: 10.3389/fphar.2022.904942
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Molecular mechanism of the oxidative stress disorder.
Oxidative stress (OS) markers of women with polycystic ovary syndrome (PCOS).
| Biomarkers evaluating the OS level | Location and source | OS levels in PCOS patients ( | Reference |
|---|---|---|---|
| p47phox↑ | Plasma MNC | Normal lean controls |
|
| ROS↑; p47phox ↑; TBARS↑ | Plasma MNC | Healthy women were treated with 130 mg of dehydroepiandrosterone (DHEA) or placebo ( |
|
| TNF-α↑; IL-6 ↑; IL-1β↑ | Plasma MNC | Healthy normal lean controls |
|
| Prolidase activities↑, TOS↑, OSI↑; TAS↓ | Plasma | Healthy normal controls |
|
| Fetuin-A↑; Lipid fractions→; MDA→; MPO→; GSH↓; SOD→ | Serum | Healthy control women |
|
| MDA→OR↑; TAC→; CoQ10 ↓ | Plasma MNC | Normal weight PCOS |
|
| TOS↑; AOPPs↑; MDA↓; PAB↑; TAS↓; SOD↓; PON1→ | Plasma | Non-obese women with PCOS |
|
| SOD↓; MDA↑; SOD↓; TAA↓; VC→; VE↓; RET↓ | Plasma | Healthy control women |
|
TOS, total oxidant status; OSI, oxidative stress index; TAS, total antioxidant status; MDA, malondialdehyde; MPO, myeloperoxidase; GSH, glutathione; SOD, superoxide dismutase; TAC, total antioxidant capacity; PAB, pro-oxidant–antioxidant balance; PON1, paraoxonase 1; AOPPs, advanced oxidation protein products; TAA, total antioxidant activity; VC, vitamin C; VE, vitamin E; RET, retinol